HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

99mTc-hR3 monoclonal antibody

a humanized immunoconjugate directed towards the epidermal growth factor receptor

Also Known As:

99mTc-hR3; DiaCIM; monoclonal antibody 99mTc-hR3

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Spicer, James: 1 article (04/2005)

Related Diseases

1.	Pancreatic Neoplasms (Pancreatic Cancer) 04/01/2005 - "A joint venture between YM BioSciences (formerly York Medical) and The Center of Molecular Immunology is collaborating with Oncoscience in Europe for the development of a humanized monoclonal antibody, nimotuzumab, for the potential treatment (TheraCIM and RadioTheraCIM) and diagnosis (DiaCIM) of cancers of epithelial origin, such as breast, lung, head and neck, and pancreatic cancer. "
2.	Neoplasms (Cancer) 04/01/2005 - "A joint venture between YM BioSciences (formerly York Medical) and The Center of Molecular Immunology is collaborating with Oncoscience in Europe for the development of a humanized monoclonal antibody, nimotuzumab, for the potential treatment (TheraCIM and RadioTheraCIM) and diagnosis (DiaCIM) of cancers of epithelial origin, such as breast, lung, head and neck, and pancreatic cancer. "

Related Drugs and Biologics

1.	Monoclonal Antibodies
2.	TheraCIM
3.	nimotuzumab